DexCom Rally Fueled by Strong Q2 Results, Margin Gains and Aggressive Buybacks
DexCom shares jumped sharply after the company reported second-quarter 2026 results that exceeded consensus across key metrics. Strong revenue and adjusted EPS, improved gross margins tied to manufacturing gains and product rollout, updated full-year guidance, sizable free cash flow and a large share-repurchase program combined with analyst target …